This finding not only indicates that GDF15 is implicated in the pathogenesis of PAH vascular lesions but also shows that the pulmonary circulation affects the muscle mass of patients with PAH through a GDF15-mediated endocrine mechanism. The gene discussed is GDF15; the disease is pulmonary arterial hypertension.